These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32619641)

  • 21. [Induction in vitro and stability of Mycobacterium tuberculosis resistance to ofloxacin].
    Yang H; Hu Z; Sha W; Lu J; Cui Z; Wang J; Huang X; Xiao H
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Apr; 48(4):318-23. PubMed ID: 24969458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.
    Kambli P; Ajbani K; Sadani M; Nikam C; Shetty A; Udwadia Z; Rodwell TC; Catanzaro A; Rodrigues C
    Tuberculosis (Edinb); 2015 Mar; 95(2):137-41. PubMed ID: 25522842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.
    Pantel A; Petrella S; Matrat S; Brossier F; Bastian S; Reitter D; Jarlier V; Mayer C; Aubry A
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4524-9. PubMed ID: 21768507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016).
    Kateete DP; Kamulegeya R; Kigozi E; Katabazi FA; Lukoye D; Sebit SI; Abdi H; Arube P; Kasule GW; Musisi K; Dlamini MG; Khumalo D; Joloba ML
    BMC Pulm Med; 2019 Jul; 19(1):124. PubMed ID: 31291943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
    Chang KC; Yew WW; Chan RC
    J Antimicrob Chemother; 2010 Aug; 65(8):1551-61. PubMed ID: 20542907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
    Bakuła Z; Napiórkowska A; Kamiński M; Augustynowicz-Kopeć E; Zwolska Z; Bielecki J; Jagielski T
    J Microbiol Immunol Infect; 2016 Jun; 49(3):439-44. PubMed ID: 26117528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.
    Chien JY; Chiu WY; Chien ST; Chiang CJ; Yu CJ; Hsueh PR
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2090-6. PubMed ID: 26787695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterisation of drug resistance-associated mutations among clinical multidrug-resistant Mycobacterium tuberculosis isolates from Hebei Province, China.
    Li Q; Wang Y; Li Y; Gao H; Zhang Z; Feng F; Dai E
    J Glob Antimicrob Resist; 2019 Sep; 18():168-176. PubMed ID: 30926465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.
    Singh P; Jain A; Dixit P; Prakash S; Jaiswal I; Venkatesh V; Singh M
    J Antibiot (Tokyo); 2015 Jan; 68(1):63-6. PubMed ID: 25052485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.
    Aubry A; Veziris N; Cambau E; Truffot-Pernot C; Jarlier V; Fisher LM
    Antimicrob Agents Chemother; 2006 Jan; 50(1):104-12. PubMed ID: 16377674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients.
    Kabir S; Tahir Z; Mukhtar N; Sohail M; Saqalein M; Rehman A
    BMC Pulm Med; 2020 May; 20(1):138. PubMed ID: 32393213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular identification of mutations associated with anti-tuberculosis drug resistance among strains of Mycobacterium tuberculosis.
    Abbadi SH; Sameaa GA; Morlock G; Cooksey RC
    Int J Infect Dis; 2009 Nov; 13(6):673-8. PubMed ID: 19138546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
    Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
    Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.
    Cheng AF; Yew WW; Chan EW; Chin ML; Hui MM; Chan RC
    Antimicrob Agents Chemother; 2004 Feb; 48(2):596-601. PubMed ID: 14742214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of drug resistance genotypes between Beijing and non-Beijing family strains of Mycobacterium tuberculosis in Korea.
    Park YK; Shin S; Ryu S; Cho SN; Koh WJ; Kwon OJ; Shim YS; Lew WJ; Bai GH
    J Microbiol Methods; 2005 Nov; 63(2):165-72. PubMed ID: 15893392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003.
    Huang TS; Kunin CM; Shin-Jung Lee S; Chen YS; Tu HZ; Liu YC
    J Antimicrob Chemother; 2005 Dec; 56(6):1058-62. PubMed ID: 16204341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subpopulation analysis of heteroresistance to fluoroquinolone in Mycobacterium tuberculosis isolates from Beijing, China.
    Zhang X; Zhao B; Liu L; Zhu Y; Zhao Y; Jin Q
    J Clin Microbiol; 2012 Apr; 50(4):1471-4. PubMed ID: 22259208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study on the prevalence of Beijing genotype Mycobacterium tuberculosis and its relationship with second-line anti-tuberculosis drug resistance].
    Liang C; Zhang XX; Xing Q; Yi JL; Zhang YQ; Li CY; Liu Y; Tang SJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Apr; 43(4):356-361. PubMed ID: 32294818
    [No Abstract]   [Full Text] [Related]  

  • 39. Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance.
    Suzuki Y; Nakajima C; Tamaru A; Kim H; Matsuba T; Saito H
    Int J Antimicrob Agents; 2012 May; 39(5):435-9. PubMed ID: 22421328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotype analysis of ofloxacin-resistant multidrug-resistant
    Gupta A; Sinha P; Rathod S; Shanmugam SK; Uma Devi KR; Anupurba S; Nema V
    Indian J Med Res; 2020 Apr; 151(4):361-370. PubMed ID: 32461400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.